Vol. 7, Issue 5 (2018)

Materials and methods: A prospective – observational study was carried out in diabetes mellitus patients with history on oral hypoglycemic therapy on 10 months period of time. Patient’s demographic details were previous medical and medication history of DM and duration on oral hypoglycemic drugs was collected. And evaluate cost minimization analysis and SF-36 questionnaires using with help of paired t-test, mean, standard deviation.

Results: The study results showed that the individual drugs of oral hypoglycemic drugs cost minimization-the order of cost list to cheapest drug prescribed was below: Voglibose> Gliclazide> glimepiride> metformin> Glipizide. The combination drugs of oral hypoglycemic drugs cost- minimization- the order of cost list to cheapest drug prescribed was below: Glimepride+metformin+voglibose>Glimepiride+metformin>Linagliptin+metformin>Voglibose+metformin>Vidagliptin+metformin>Acarbose+metformin>glibenclamide+metformin>glipizide+metformin. General health, pain, energy and emotions were showed significant P value less than 0.05. The limitation of activity, physical health problems, emotional health problems, social activity, social activity and general health were showed non-significant.

Conclusion: A Pharmacoeconomic approach was commonly used to evaluate the health benefit of drug treatments to gain good value for money. Cost minimization analysis was the evident that same drug molecule varying in costs has same drug strength content. To improve the health related quality of life the patients would awareness of the disease. The patient with economically weak the cost minimization analysis was much helpful in improves the quality of life and disease progression.